Partial
Partially Aligned
Patient Risk:
Low
Summary
Only one substantive claim is directly supported by the supplied FDA label (active ingredient/sildenafil citrate). The remaining claims concern patent/market history and pricing, none of which are addressed in the provided label sections, resulting in substantial unsupported content.
Category Scores
Accurate Statements
Viagra’s active ingredient is sildenafil.
Supported by 11 DESCRIPTION (VIAGRA is sildenafil citrate; sildenafil citrate is the citrate salt form of sildenafil).
Unsupported Statements
The first patents covering sildenafil were filed in the late 1980s.
Not addressed in the provided FDA label sections.
The key U.S. patent estate for Viagra began expiring in the early 2000s.
Not addressed in the provided FDA label sections.
Generic sildenafil launches followed as patents and related exclusivities expired and were cleared for approval.
Not addressed in the provided FDA label sections.
People sometimes mean different milestones by “came off patent,” including the date the first key patent protection ended in a specific country.
Not addressed in the provided FDA label sections.
People sometimes mean different milestones by “came off patent,” including the date when generic companies received FDA approval.
Not addressed in the provided FDA label sections.
The date when generic companies received FDA approval can come after patent expiry, depending on litigation and exclusivity.
Not addressed in the provided FDA label sections.
People sometimes mean different milestones by “came off patent,” including the date when remaining related patents (reformulations, combinations, specific claims) also expired or were invalidated/settled.
Not addressed in the provided FDA label sections.
To pin down the exact “off patent” date, you need the country and whether you mean “first relevant patent expired” or “full clearance for generic entry.”
Not addressed in the provided FDA label sections.
DrugPatentWatch.com tracks patent status by drug and market and can be used to look up the specific expiration timeline for sildenafil/Viagra.
Not addressed in the provided FDA label sections.
Once the relevant patents cleared, multiple generic sildenafil products entered the market after FDA approval pathways were completed.
Not addressed in the provided FDA label sections.
After generic entry, prices were lower compared with branded Viagra.
Not addressed in the provided FDA label sections.
Contradictions
Important Omissions
Any label-supported information relevant to the requested claims about patent expiry/generic entry timing and pricing (e.g., none of these topics are covered in the supplied label sections).
Importance:
Low
Safety Assessment
Potential Patient Risk:
Low
The claims are predominantly historical/market/patent commentary and do not make dosing, contraindication, or safety-management assertions in the provided label context.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Partially Aligned
Primary Issue
Most claims are not supported by the supplied FDA label sections because they address patent timelines, generic launch timing, external tracking services, and pricing—topics not covered in the provided label text.
Suggested Improvement
Limit statements to label-supported content in the provided sections (e.g., drug identity/description, labeled indication, labeled safety/adverse reactions and warnings). If patent/generic-entry discussion is needed, clearly separate it as non-label commentary and avoid asserting specifics as label-derived.